116 related articles for article (PubMed ID: 7803295)
1. Over-expression of the MDM2 gene is found in some cases of haematological malignancies.
Quesnel B; Preudhomme C; Oscier D; Lepelley P; Collyn-d'Hooghe M; Facon T; Zandecki M; Fenaux P
Br J Haematol; 1994 Oct; 88(2):415-8. PubMed ID: 7803295
[TBL] [Abstract][Full Text] [Related]
2. Lack of MDM2 amplification in human leukaemia.
Ridge SA; Dyer M; Greaves MF; Wiedemann LM
Br J Haematol; 1994 Feb; 86(2):407-9. PubMed ID: 8199038
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of the MDM2 oncogene in leukemia and lymphoma.
Watanabe T; Ichikawa A; Saito H; Hotta T
Leuk Lymphoma; 1996 May; 21(5-6):391-7, color plates XVI following 5. PubMed ID: 9172803
[TBL] [Abstract][Full Text] [Related]
4. Oncoprotein MDM2 overexpression is associated with poor prognosis in distinct non-Hodgkin's lymphoma entities.
Møller MB; Nielsen O; Pedersen NT
Mod Pathol; 1999 Nov; 12(11):1010-6. PubMed ID: 10574597
[TBL] [Abstract][Full Text] [Related]
5. Expression of p53, MDM2, p21waf1, bcl-2, and retinoblastoma gene proteins in myelodysplastic syndrome after autologous bone marrow transplantation for lymphoma.
Brynes RK; Wilson CS; Kim AB; McCourty A
Mod Pathol; 1997 Nov; 10(11):1120-7. PubMed ID: 9388063
[TBL] [Abstract][Full Text] [Related]
6. Rearrangement and expression of MDM2 oncogene in chronic lymphocytic leukemia.
Huang YQ; Raphael B; Buchbinder A; Li JJ; Zhang WG; Friedman-Kien AE
Am J Hematol; 1994 Oct; 47(2):139-41. PubMed ID: 8092130
[TBL] [Abstract][Full Text] [Related]
7. The MDM2 oncogene overexpression in chronic lymphocytic leukemia and low-grade lymphoma of B-cell origin.
Watanabe T; Hotta T; Ichikawa A; Kinoshita T; Nagai H; Uchida T; Murate T; Saito H
Blood; 1994 Nov; 84(9):3158-65. PubMed ID: 7949188
[TBL] [Abstract][Full Text] [Related]
8. MDM2 gene amplification and expression in non-small-cell lung cancer: immunohistochemical expression of its protein is a favourable prognostic marker in patients without p53 protein accumulation.
Higashiyama M; Doi O; Kodama K; Yokouchi H; Kasugai T; Ishiguro S; Takami K; Nakayama T; Nishisho I
Br J Cancer; 1997; 75(9):1302-8. PubMed ID: 9155050
[TBL] [Abstract][Full Text] [Related]
9. MDM2 gene amplification and transcript levels in human sarcomas: relationship to TP53 gene status.
Flørenes VA; Maelandsmo GM; Forus A; Andreassen A; Myklebost O; Fodstad O
J Natl Cancer Inst; 1994 Sep; 86(17):1297-302. PubMed ID: 8064888
[TBL] [Abstract][Full Text] [Related]
10. Abnormalities of the P53, MDM2, BCL2 and BAX genes in acute leukemias.
Wojcik I; Szybka M; Golanska E; Rieske P; Blonski JZ; Robak T; Bartkowiak J
Neoplasma; 2005; 52(4):318-24. PubMed ID: 16059649
[TBL] [Abstract][Full Text] [Related]
11. Absence of amplification of MDM2 gene, a regulator of p53 function, in myelodysplastic syndromes.
Preudhomme C; Quesnel B; Vachee A; Lepelley P; Collyn-D'Hooghe M; Wattel E; Fenaux P
Leukemia; 1993 Aug; 7(8):1291-3. PubMed ID: 8350630
[TBL] [Abstract][Full Text] [Related]
12. p21WAF1/CIP1 and MDM2 expression in non-Hodgkin's lymphoma and their relationship to p53 status: a p53+, MDM2-, p21-immunophenotype associated with missense p53 mutations.
Villuendas R; Pezzella F; Gatter K; Algara P; Sánchez-Beato M; Martínez P; Martínez JC; Muñoz K; García P; Sánchez L; Kocialkowsky S; Campo E; Orradre JL; Piris MA
J Pathol; 1997 Jan; 181(1):51-61. PubMed ID: 9072003
[TBL] [Abstract][Full Text] [Related]
13. Gene abnormalities in multiple myeloma; the relevance of TP53, MDM2, and CDKN2A.
Elnenaei MO; Gruszka-Westwood AM; A'Hernt R; Matutes E; Sirohi B; Powles R; Catovsky D
Haematologica; 2003 May; 88(5):529-37. PubMed ID: 12745272
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical detection of p53, mdm2, waf1/p21, and Ki67 proteins in bone marrow biopsies in myelodysplastic syndroms, acute myelogenous leukaemias and chronic myeloproliferative disorders.
Kanavaros P; Stefanaki K; Rontogianni D; Darivianaki K; Vlychou M; Papadaki E; Eliopoulos G; Bakiri M; Matsouka C; Kakolyris S; Georgoulias V
Clin Exp Pathol; 1999; 47(5):231-8. PubMed ID: 10598372
[TBL] [Abstract][Full Text] [Related]
15. p53, Mdm2, and c-Myc overexpression is associated with a poor prognosis in aggressive non-Hodgkin's lymphomas.
Pagnano KB; Vassallo J; Lorand-Metze I; Costa FF; Saad ST
Am J Hematol; 2001 Jun; 67(2):84-92. PubMed ID: 11343379
[TBL] [Abstract][Full Text] [Related]
16. Expression of the c-mpl proto-oncogene in human hematologic malignancies.
Vigon I; Dreyfus F; Melle J; Viguié F; Ribrag V; Cocault L; Souyri M; Gisselbrecht S
Blood; 1993 Aug; 82(3):877-83. PubMed ID: 8393355
[TBL] [Abstract][Full Text] [Related]
17. MDM2 gene amplification and lack of p53 point mutations in Hodgkin and Reed-Sternberg cells: results from single-cell polymerase chain reaction and molecular cytogenetic studies.
Küpper M; Joos S; von Bonin F; Daus H; Pfreundschuh M; Lichter P; Trümper L
Br J Haematol; 2001 Mar; 112(3):768-75. PubMed ID: 11260082
[TBL] [Abstract][Full Text] [Related]
18. The MDM2 oncogene is rarely amplified in human lymphoid tumors and does not correlate with p53 gene expression.
Cesarman E; Liu YF; Knowles DM
Int J Cancer; 1994 Feb; 56(3):457-8. PubMed ID: 8314334
[No Abstract] [Full Text] [Related]
19. MDM2 expression in lymphoid cells and reactive and neoplastic lymphoid tissue. Comparative study with p53 expression.
Martinez JC; Mateo M; Sánchez-Beato M; Villuendas R; Orradre JL; Algara P; Sánchez-Verde L; García P; López C; Martínez P
J Pathol; 1995 Sep; 177(1):27-34. PubMed ID: 7472776
[TBL] [Abstract][Full Text] [Related]
20. CEBPA polymorphisms and mutations in patients with acute myeloid leukemia, myelodysplastic syndrome, multiple myeloma and non-Hodgkin's lymphoma.
Fuchs O; Provaznikova D; Kocova M; Kostecka A; Cvekova P; Neuwirtova R; Kobylka P; Cermak J; Brezinova J; Schwarz J; Markova J; Salaj P; Klamova H; Maaloufova J; Lemez P; Novakova L; Benesova K
Blood Cells Mol Dis; 2008; 40(3):401-5. PubMed ID: 18182175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
